{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:07:14Z","timestamp":1792606034574,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jpba.2023.115279","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T11:15:50Z","timestamp":1675250150000},"page":"115279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS\/MS and its application in acute myeloid leukemia patients"],"prefix":"10.1016","volume":"227","author":[{"given":"Ping","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115279_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2023.115279_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.jpba.2023.115279_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.jpba.2023.115279_bib4","unstructured":"Venclexta (venetoclax) (2016) US prescribing information (2016) AbbVie Inc., North Chicago, IL. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208573s009lbl.pdf\u3009."},{"key":"10.1016\/j.jpba.2023.115279_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkp507","article-title":"Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006","volume":"65","author":"Hahn-Ast","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2023.115279_bib6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/myc.13148","article-title":"Breakthrough invasive fungal infections: who is at risk?","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.jpba.2023.115279_bib7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0149-2918(03)80126-1","article-title":"Voriconazole","volume":"25","author":"Jeu","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2023.115279_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3904\/kjim.2017.109","article-title":"Voriconazole-refractory invasive aspergillosis","volume":"32","author":"Park","year":"2017","journal-title":"Korean J. Intern Med"},{"key":"10.1016\/j.jpba.2023.115279_bib9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115279_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-016-0485-9","article-title":"Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers","volume":"37","author":"Salem","year":"2017","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jpba.2023.115279_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/jcph.730","article-title":"Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study","volume":"56","author":"Agarwal","year":"2016","journal-title":"J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.jpba.2023.115279_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2023.115279_bib13","unstructured":"USA Department of Health and Human Services Food and Drug Administration. Bioanalytical method validation guidance for industry (2022). \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m10-bioanalytical-method-validation-and-study-sample-analysis.pdf\u3009."},{"issue":"4","key":"10.1016\/j.jpba.2023.115279_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2023.115279_bib15","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115279_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","author":"Eisenmann","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115279_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4155\/bio-2021-0207","article-title":"LC-MS\/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction","volume":"14","author":"Reddy","year":"2022","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2023.115279_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab. Dispos."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:25:51Z","timestamp":1760001951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":18,"alternative-id":["S0731708523000481"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115279","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS\/MS and its application in acute myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115279"}}